Ocular Therapeutix (NASDAQ:OCUL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.
According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. “
A number of other research firms also recently issued reports on OCUL. BidaskClub upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Sunday, December 2nd. Cantor Fitzgerald raised their price target on shares of Ocular Therapeutix from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 3rd. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, December 4th. Cowen restated a “buy” rating and issued a $13.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, December 4th. Finally, Raymond James began coverage on shares of Ocular Therapeutix in a research report on Wednesday, November 14th. They issued a “strong-buy” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $12.61.
Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.05). Ocular Therapeutix had a negative net margin of 3,013.97% and a negative return on equity of 136.09%. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.45 million. Equities analysts forecast that Ocular Therapeutix will post -1.47 earnings per share for the current year.
In other news, Director Richard L. Md Lindstrom acquired 56,441 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The shares were purchased at an average cost of $4.33 per share, for a total transaction of $244,389.53. Following the transaction, the director now directly owns 100,000 shares in the company, valued at approximately $433,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.90% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in OCUL. JGP Global Gestao de Recursos Ltda. acquired a new position in Ocular Therapeutix during the 4th quarter valued at about $50,000. Bank of America Corp DE increased its stake in Ocular Therapeutix by 197.0% during the 4th quarter. Bank of America Corp DE now owns 26,271 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 17,425 shares during the period. Trexquant Investment LP acquired a new position in Ocular Therapeutix during the 3rd quarter valued at about $139,000. Rhumbline Advisers increased its stake in Ocular Therapeutix by 50.3% during the 4th quarter. Rhumbline Advisers now owns 43,465 shares of the biopharmaceutical company’s stock valued at $173,000 after buying an additional 14,551 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Ocular Therapeutix during the 3rd quarter valued at about $200,000. 52.41% of the stock is currently owned by hedge funds and other institutional investors.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.